Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
Year-over-year operating income growth rate
| Period | Value |
|---|---|
| Q3 2025 | 64.15% |
| Q2 2025 | 516.95% |
| Q1 2025 | -83.38% |
| Q4 2024 | -22.74% |
| Q3 2024 | 26.41% |
| Q2 2024 | 46.42% |
| Q1 2024 | -33.93% |
| Q4 2023 | 6.44% |
| Q3 2023 | 91.85% |
| Q2 2023 | 164.45% |
| Q1 2023 | -210.44% |
| Q4 2022 | 17.77% |
| Q3 2022 | 60.51% |
| Q2 2022 | 1664.52% |
| Q1 2022 | 108.54% |
| Q4 2021 | -181.57% |
| Q3 2021 | -29.14% |
| Q2 2021 | 99.37% |
| Q1 2021 | -56.13% |
| Q4 2020 | 262.08% |
| Q3 2020 | -157.83% |
| Q2 2020 | 30.05% |
| Q1 2020 | 20.89% |
| Q4 2019 | -45.93% |
| Q3 2019 | 161.92% |
| Q2 2019 | 134.06% |
| Q1 2019 | -561.80% |
| Q4 2018 | -59.74% |
| Q3 2018 | 3033.21% |
| Q2 2018 | 95.05% |
| Q1 2018 | -416.44% |
| Q4 2017 | 297.40% |
| Q3 2017 | 89.53% |
| Q2 2017 | 28.35% |
| Q1 2017 | -72.82% |
| Q4 2016 | -20.33% |
| Q3 2016 | 8.11% |
| Q2 2016 | -100.55% |
| Q1 2016 | 32.17% |
| Q4 2015 | 14.22% |